Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China

Table 2 Clinical characteristics of participants (n = 456)

Parameter
Route of HCV acquisition^a
Blood Transfusion	271 (59.4)
Intravenous drug abuse	17 (3.7)
Dental treatment	92 (21.1)
Other	87 (19.1)
Number of moderate or severe symptoms of discomfort, n (%)^b
0	383 (84.0%)
1	56 (12.3%)
≥2	17 (3.7%)
Extrahepatic manifestations, n (%)^c
Yes	45 (9.7%)
No	411 (90.3%)
Cirrhosis, n (%)
Yes	44 (9.6%)
No	412 (90.4%)
Beck’s Depression Score, median (Q1, Q3)
<17	411 (90.1%)
≥17	45 (9.7%)
HCV Genotype
1	210 (46.1%)
2	116 (25.4%)
Else	129 (28.3%)
Log₁₀HCV RNA, IU/mL, (Q1, Q3)	6.10 (5.34, 6.55)
Duration of follow-up, median months, (Q1, Q3)	69.6 (69, 70)
Antiviral therapy during follow-up, n (%)
Yes	335 (73.5%)
No	121 (26.5%)
Achieving SVR 12 during follow-up, n (%)
Yes	292 (64.0%)
No	164 (36.0%)
Achieving SVR 24 during follow-up, n (%)
Yes	282 (61.8%)
No	174 (38.2%)

^a Other route of HCV acquisition: sex, long-term exposure history to HCV patient, tattoo, piercings, intra-exam and treatment, and etc. Patients may report more than one route of HCV acquisition. ^b Uncomfortable symptoms: moderate or above malaise, appetite decrease, nausea, discomfort of right hypochondrium, fever, xanthochromia, xanthurenic and other uncomfortable symptoms. ^c Extrahepatic manifestation: Behcet’s disease, cryoglobulinemia, prediabetes, diabetes, hyperlipidemia, fatty liver, insulin resistance, fibromyalgia, membranoproliferative glomerulonephritis, membranous nephropathy, multiple myeloma, Raynaud’s syndrome, rheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosus, thyroid dysfunction, skin lesions, hypertrophic cardiomyopathy, porphyria cutanea tarda, lichen planus, vasculitis, pulmonary fibrosis. SVR 12/24, Sustained virologic response 12/24 weeks post treatment

ISSN: 1471-2334